Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freshworks Inc (FRSH) vs Smith & Nephew plc (SNN) Price & Performance

Freshworks IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Freshworks Inc vs Smith & Nephew plc — how do they compare? Freshworks Inc trades at $13.83 (market cap $3.56B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3.1× Freshworks Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Smith & Nephew plc for 120 Days on average.

FRSHSNN
Market Cap
$3.56B$11.10B
Volume
9,066,4541,051,703
Sector
TechnologyHealth
52-Week High
$13.92$37.17
52-Week Low
$6.88$26.42
Typical Hold Time
39 Days120 Days
Enterprise Value
$2.93B$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freshworks Inc

Freshworks (FRSH) trades at $13.86, up 1.91% today, reflecting positive momentum following its Q2 2026 earnings beat. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests it may be approaching overbought territory. Fundamentally, the company has achieved a significant turnaround, posting its first GAAP profitable quarter in 2026 with revenue growth of 16% year-over-year, driven by strength in its employee experience portfolio and cost discipline.

The outlook is positive, supported by a 50% analyst buy rating and a consensus price target of $14.60, implying modest upside. Key opportunities include continued AI monetization and market share gains, while risks involve heightened competition in the SaaS sector and the need to sustain recent profitability improvements amid economic uncertainty.

Smith & Nephew plc

SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.

The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FRSH
0% Buy100% Sell
Avg holding period · 39 Days
SNN

No sentiment data available yet.

Top news

Latest headlines on both assets

About Freshworks Inc

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.

Read more on FRSH →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →